Compare Torrent Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs PFIZER - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA PFIZER TORRENT PHARMA/
PFIZER
 
P/E (TTM) x 36.2 43.6 83.0% View Chart
P/BV x 9.2 7.2 126.6% View Chart
Dividend Yield % 0.7 0.5 140.8%  

Financials

 TORRENT PHARMA   PFIZER
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
PFIZER
Mar-19
TORRENT PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,9643,840 51.1%   
Low Rs1,2452,080 59.9%   
Sales per share (Unadj.) Rs453.4455.0 99.7%  
Earnings per share (Unadj.) Rs25.893.8 27.5%  
Cash flow per share (Unadj.) Rs62.3109.4 56.9%  
Dividends per share (Unadj.) Rs17.0022.50 75.6%  
Dividend yield (eoy) %1.10.8 139.4%  
Book value per share (Unadj.) Rs279.2658.2 42.4%  
Shares outstanding (eoy) m169.2245.75 369.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.56.5 54.4%   
Avg P/E ratio x62.231.6 197.2%  
P/CF ratio (eoy) x25.827.1 95.2%  
Price / Book Value ratio x5.74.5 127.8%  
Dividend payout %65.924.0 274.8%   
Avg Mkt Cap Rs m271,513135,420 200.5%   
No. of employees `00013.62.6 516.8%   
Total wages/salary Rs m14,0383,238 433.5%   
Avg. sales/employee Rs Th5,642.67,911.4 71.3%   
Avg. wages/employee Rs Th1,032.41,230.9 83.9%   
Avg. net profit/employee Rs Th320.91,630.7 19.7%   
INCOME DATA
Net Sales Rs m76,72820,815 368.6%  
Other income Rs m5711,674 34.1%   
Total revenues Rs m77,29922,489 343.7%   
Gross profit Rs m19,8315,712 347.2%  
Depreciation Rs m6,177714 865.2%   
Interest Rs m5,03873 6,910.2%   
Profit before tax Rs m9,1876,599 139.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,2542,309 54.3%   
Profit after tax Rs m4,3634,291 101.7%  
Gross profit margin %25.827.4 94.2%  
Effective tax rate %13.635.0 39.0%   
Net profit margin %5.720.6 27.6%  
BALANCE SHEET DATA
Current assets Rs m50,37527,167 185.4%   
Current liabilities Rs m51,6538,917 579.3%   
Net working cap to sales %-1.787.7 -1.9%  
Current ratio x1.03.0 32.0%  
Inventory Days Days9268 135.8%  
Debtors Days Days6830 226.9%  
Net fixed assets Rs m83,6488,862 943.9%   
Share capital Rs m846458 185.0%   
"Free" reserves Rs m46,39729,656 156.5%   
Net worth Rs m47,24430,113 156.9%   
Long term debt Rs m39,12925 156,516.8%   
Total assets Rs m141,20939,400 358.4%  
Interest coverage x2.891.5 3.1%   
Debt to equity ratio x0.80 99,765.1%  
Sales to assets ratio x0.50.5 102.9%   
Return on assets %6.711.1 60.1%  
Return on equity %9.214.2 64.8%  
Return on capital %12.322.1 55.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,103428 5,160.5%   
Fx outflow Rs m5,522786 702.1%   
Net fx Rs m16,581-358 -4,630.3%   
CASH FLOW
From Operations Rs m17,981978 1,838.3%  
From Investments Rs m-2,413351 -687.0%  
From Financial Activity Rs m-13,145-1,099 1,196.6%  
Net Cashflow Rs m2,380231 1,031.3%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 7.0 7.5 93.6%  
FIIs % 12.6 4.9 257.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 23.7 37.1%  
Shareholders   26,511 85,207 31.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   CIPLA  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  PIRAMAL ENTERPRISES  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 1,708 Points Today(Closing)

Indian share markets witnessed huge selling pressure today as fears that the government could go for stricter lockdowns.

Related Views on News

DR. LAL PATHLABS at All Time High; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Apr 12, 2021 | Updated on Apr 12, 2021

DR. LAL PATHLABS share price has hit an all time high at Rs 3,255 (up 2.4%). The BSE HEALTHCARE Index is down by 0.2%. Among the top gainers in the BSE HEALTHCARE Index today are DR. LAL PATHLABS (up 2.4%) and DR. REDDYS LAB (up 3.1%). The top losers include SYNGENE INTERNATIONAL (down 0.2%) and AJANTA PHARMA (down 0.4%).

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Apr 12, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS